Tardive Dyskinesia Impacts Patients and Caregivers
By Lori Solomon HealthDay Reporter
FRIDAY, Dec. 8, 2023 -- Tardive dyskinesia (TD) poses a substantial burden for both caregivers and patients, according to a study published online Nov. 28 in the Journal of Patient-Reported Outcomes.
Rakesh Jain, M.D., M.P.H., from the Texas Tech University School of Medicine-Permian Basin in Midland, and colleagues conducted an online survey to assess patient and caregiver burden of TD. The analysis included 162 unpaid caregivers for patients with diagnoses of TD and schizophrenia, bipolar disorder, and/or major depressive disorder.
The researchers found that across physical, psychological, and social domains, most caregivers (82.7 percent) reported that TD had a severe impact on the cared-for patients, and 23.5 percent reported a severe impact of TD on their own lives. Impact on caregivers included experiencing activity impairment (46.4 percent), and among 136 employed caregivers, 49.5 percent experienced overall work impairment because of TD-related caregiving.
"As subjective caregiver burden is known to be a risk factor for anxiety in unpaid caregivers, these results highlight the importance of recognizing the incremental negative impact of TD on caregivers and may help health care providers develop assessment tools for holistic evaluation of the caregiver burden in TD," the authors write. "These results also demonstrate that TD imposes a substantial burden on caregivers' professional lives, which should be taken into account when considering the societal burden of TD."
Several authors disclosed financial ties to pharmaceutical companies, including Teva; Teva Branded Pharmaceutical Products R&D funded the study
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.